MTHFD2 and neoplasm: Further investigation into the mechanisms of deiodination and the development of strategies to counteract this process will be essential for the advancement of [125I]anastrozole and [125I]epirubicin as targeted radiopharmaceuticals for MTHFD2-driven neoplasms.